Tyrosinemia is a rare genetic disease caused by mutations on genes that codify enzymes responsible for tyrosine metabolism. Considering that tyrosinemics patients usually present symptoms associated with central nervous system alterations that ranges from slight decreases in intelligence to severe mental retardation, we decided to investigate whether acute and chronic administration of L-tyrosine in rats would affect acetylcholinesterase mRNA expression and enzymatic activity during their development. In our acute protocol, Wistar rats (10 and 30 days old) were killed one hour after a single intraperitoneal L-tyrosine injection (500 mg/kg) or saline. Chronic administration consisted of L-tyrosine (500 mg/kg) or saline injections 12 h apart for 24 days in Wistar rats (7 days old) and rats were killed 12 h after last injection. Acetylcholinesterase activity was measured by Ellman's method and acetylcholinesterase expression was carried out by a semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay. We observed that acute (10 and 30 days old rats) and chronic L-tyrosine administration increased acetylcholinesterase activity in serum and all tested brain areas (hippocampus, striatum and cerebral cortex) when compared to control group. Moreover, there was a significant decrease in mRNA levels of acetylcholinesterase in hippocampus was observed after acute protocol (10 and 30 days old rats) and in striatum after chronic protocol. In case these alterations also occur in the brain of the patients, our results may explain, at least in part, the neurological sequelae associated with high plasma concentrations of tyrosine seen in patients affected by tyrosinemia type II.
Introduction
Tyrosine is an amino acid degraded primarily in the hepatocytes being both glucogenic and ketogenic. Under most circumstances, tyrosine degradation rate is determined by tyrosine aminotransferase activity (Held, 2006) but deficiency of any of the catabolic enzymes involved will lead to an accumulation of tyrosine in tissues, cerebrospinal fluid (CSF), blood and urine leading to formation of characteristic crystals (Scott, 2006) . Tyrosinemia is a rare disease and caused by genetic variants in one of the genes that codify enzyme responsible for tyrosine metabolism (Nakamura et al., 2007) . In humans, three distinct autosomal recessive diseases of tyrosine catabolism have been identified: tyrosinemia type I (deficiency of fumarylacetoacetate hydrolase), tyrosinemia type II (deficiency of tyrosine aminotransferase) and tyrosinemia type III (deficiency of 4-hydroxyphenylpyruvate dioxygenase) (Held, 2006; Mitchell et al., 2001) .
Tyrosinemia type II is characterized by the highest level of tyrosine among all tyrosinemias. Although brain tyrosine concentration in type II patients is not known, it has been reported plasma tyrosine levels exceeding 1000 mM in untreated type II patients (Scott, 2006) with results ranging from 370 to 3420 mM (normal <90 mM) along with some tyrosine derivatives accumulation (4-hydroxyphenylpyruvic acid, 4-hydroxyphenyllactic acid and 4-hydroxyphenylacetic acid). Eyes, skin and nervous system are the main organs affected by tyrosine aminotransferase deficiency (Held, 2006; Goldsmith et al., 1973; Macsai et al., 2001; Mitchell et al., 2001; Rabinowitz et al., 1995; Valikhani et al., 2005 slight decreases in intelligence to severe mental retardation and may be associated with microcephaly, tremor, ataxia, self-mutilating behavior, fine motor coordination disturbances, language deficits, and convulsions (Goldsmith et al., 1973; Lemonnier et al., 1979; Macsai et al., 2001; Mitchell et al., 2001; Rabinowitz et al., 1995; Valikhani et al., 2005) . Little is known regarding tyrosineinduced molecular alterations that may explain these symptoms.
Alterations during neurodevelopment are expected in patients with type II tyrosinemia. L-Tyrosine can interfere in the development of cholinergic system through the dopaminergic system. This interference may occur because L-tyrosine is responsible for the syntheses of catecholamines (Mitchell et al., 2001) . According with the literature, the cholinergic system interacts with dopaminergic system, as a modulatory system. During neural development a correct and organized set of neurotransmitters and neuromodulators is essential to promote the stimuli needed affecting synaptic contact formation, synapses maturation and structural refinement of connectivity (Zhang and Poo, 2001) . Acetylcholine (Ach) is one of the major neurotransmitters involved in cortical activation, attention, memory, learning, pain, control of motor tone, locomotion and control of autonomic functions (Herlenius and Lagercrantz, 2004) . Ach acts thought specific receptors which are clustered in the postsynaptic membrane. Central cholinergic deficits are strongly related to neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases (Soreq and Seidman, 2001; Oda, 1999) .
Cholinergic transmission is mainly terminated by acetylcholinesterase (AChE: EC 3.1.1.7), a fast serine hydrolase enzyme that cleaves Ach into choline and acetate (Soreq and Seidman, 2001 ). It has been described that AChE is also involved with glial activation, cerebral blood flux, amyloid cascade, tau phosphorylation, as well as an action as adhesion protein in synaptic development and maintenance (Ballard et al., 2005) . Considering that tyrosinemia patients usually present symptoms associated with disturbances of the central nervous system and AChE plays a major role regulating cholinergic functions, we have investigated whether L-tyrosine administration would affect AChE mRNA expression and its activity in brain and serum of rats during their development.
Material and methods

Animals and reagents
Sixty Wistar rats males of different litter were obtained from Central Animal House of Universidade do Extremo Sul Catarinense. They were caged in group of five with free access to food and water and were maintained on a 12-h light-dark cycle (lights on 7:00 am) at a temperature of 23 ± 1°C. All experimental procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the Brazilian Society for Neuroscience and Behavior recommendations for animal care with the approval of the Ethics Committee from Universidade do Extremo Sul Catarinense (protocol number 42/2010). All chemical were purchased from Sigma Chemicol Co., St. Louis, MO, USA. L-Tyrosine was dissolved in saline solution (pH was adjusted to 7.4).
Administration of L-tyrosine
In our acute protocol, forty Wistar rats males (10 and 30 days old) were killed one hour after a single intraperitoneal L-tyrosine injection (500 mg/kg) or saline (n = 10 each group). Chronic administration consisted of L-tyrosine (500 mg/kg) or saline injections (n = 10 each group) 12 h apart for 24 days in twenty Wistar rats males (7 days old) and rats were killed 12 h after last injection. This dose was chosen in order to obtain L-tyrosine concentrations about 10 times normal one hour after administration (Morre et al., 1980; Bongiovanni et al., 2003) which are similar variations of plasma L-tyrosine concentration observed in patients affected by tyrosinemia type II (Mitchell et al., 2001 ). Rats' age was selected considering Ach metabolism in rodents. Ach reaches mature levels around 8 weeks after birth in rodent brain and its degradation rate increases in a time-dependent manner after birth attaining stability at 21 days of neonatal life (Berger-Sweeney and Hohmann, 1997; Lassiter et al., 1998; Mortensen et al., 1998) . Serum and brain were collected and hippocampus, striatum and cerebral cortex were dissected (Llesuy et al., 1985) . The same rats were used for both measurements: AChE activity and analysis of gene expression by semi-quantitative RT-PCR.
Acetylcholinesterase activity
For AChE assay, hippocampus, striatum and cerebral cortex were homogenized in 10 volumes 100 mM potassium-phosphate buffer (pH 7.5) and centrifuged at 1000g for 10 min. The supernatants were used for AChE activity analysis according to the method of Ellman et al. (1961) . The reaction mixture (2 ml final volume) contained 100 mM potassium-phosphate buffer, pH 7.5 and 1 mM 5,5 0 -dithiobisnitrobenzoic acid (DTNB). The method is based on the formation of the yellow anion, 5,5
0 -dithio-bis-acidnitrobenzoic, measured by absorbance at 412 nm during 2-min incubation at 25°C. The enzyme (40-50 lg of protein) was preincubated for 2 min. The reaction was initiated by adding 0.8 mM acetylthiocholine iodide (AcSCh). All samples were run in duplicate or triplicate and the enzyme activity were expressed in lmol AcSCh/h/mg of protein. Protein was measured by the method of Lowry et al. (1951) ) using bovine serum albumin as standard.
Analysis of gene expression by semi-quantitative RT-PCR
The analysis of ache mRNA expression was carried out by a semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay. Striatum, hippocampus and cerebral cortex were dissected under sterile conditions followed by a total RNA extraction using TRIzol Ò Reagente (Invitrogen, Carlsbad, CA, USA) according to the manufacturer instructions. RNA was quantified by spectrophotometry and cDNA species were synthesized with ImProm-II™ Reverse Transcription System (Promega) following the suppliers. PCR reactions for ache and b-actin genes (Keseler et al., 2005) were performed using 0.1 lM primers (ache forward: 5 0 -GAC TGC CTT TAT CTT AAT GTG-3 0 and reverse: 5 0 -CGG CTG ATG AGA GAT TCA TTG-3 0 ; b-actin forward 5 0 -TAT GCC AAC ACA GTG CTG TCT GG-3 0 ; and reverse 5 0 -TAC TCC TGC TTC CTG ATC CAC AT-3 0 ) 0.2 lM dNTP, 2 mM MgCl 2 and 0.1 U Platinum Taq DNA polymerase (Invitrogen) in a total volume of 25 lL for ache and 20 lL for b-actin. The following conditions were used for the PCR reactions: 1 min at 94°C; 1 min for annealing temperature (54°C for b-actin and 55°C for ache) and 1 min at 72°C for 35 cycles. Post-extension at 72°C was performed for 10 min. For each set of PCR reactions, negative control was included. PCR products (ache: 785 bp, b-actin: 210 bp) were analyzed on 1.5% agarose gel, containing GelRed Ò (Biotium) and visualized under ultraviolet light. The Low DNA Mass Ladder (Invitrogen) was used as molecular marker and normalization was performed employing b-actin as a constitutive gene.
Statistical analysis
Results are presented as means ± standard deviation. Assays were performed in duplicate and mean was used for statistical analysis. Tests for determination of normality and equal variances were performed to examine whether our data qualified for para-metric statistical tests. Data were normally distributed (ShapiroWilk, p > 0.05) with equal variances among samples (equal variances test, p > 0.05). Thus, the Student's t-test was used for comparison of two means. Differences between the groups were rated significant at p < 0.05. All analyses were carried out in an IBM-compatible PC computer using the Statistical Package for the Social Sciences (SPSS) software.
Results
We first examined acute and chronic administration of L-tyrosine effects on the AChE activity and after the AChE activity regulation, which could be a consequence of transcriptional control and/or posttranslational modifications. In the acute administrations of L-tyrosine in 10 and 30-day-old rats, increased AChE activity in serum and all evaluated brain areas when compared to control group (Fig. 1A and Fig. 1B ). There was a significant decrease in mRNA levels of AChE only in hippocampus after acute administration in both ages ( Fig. 2A and B) . Moreover, chronic administration of L-tyrosine has also increased AChE in serum and all analyzed brain areas (Fig. 1C) . The mRNA levels of AChE have been decreased only in striatum (Fig. 2C ).
Discussion
Our results indicate that L-tyrosine administration increases AChE activity in cerebral cortex, striatum, hippocampus and serum while decreases ache mRNA expression in hippocampus and striatum after acute and chronic administration, respectively. The method described by Ellman et al. (1961) evaluates the hydrolysis of acetylcholine, and the AChE catalyzes the hydrolysis of ACh much more rapidly than does BChE. The preferred substrate for AChE is acetylcholine (ACh), while the preferred substrates for BChE are butyrylcholine (BCh) and propionylcholine (PCh) (Tecles and Ceron, 2001; Wilson and Philip, 2005; Wilson et al., 2001) .
Ach is an essential player in the formation, maintenance and evocation of memory processes. An excess level of Ach was shown to be neurotoxic while the opposite is also true since low levels of Ach in the synaptic junction may influence memory negatively (Soreq and Seidman, 2001; Tõugu and Kesvatera, 1996) . Based on our results we can suggest that the increase in AChE activity caused by administrations of L-tyrosine may lead to a reduction of cholinergic neurotransmission efficiency due to a decrease in acetylcholine levels in the synaptic cleft, these finds can explain, at least in part, the progressive cognitive impairment and other neurological dysfunctions seen in patients affected by tyrosinemia type II. It has been speculated that the degree of CNS involvement may be correlated to abnormal high levels of plasma tyrosine (Mitchell et al., 2001) .
The development of CNS occurs in phases, which follow a precise sequence (Morgane et al., 1992) , we have chosen to study 10 and 30-day-old rats to track brain development. Slotkin et al. (2005) identified a crucial phase of vulnerability of neuronal cells, corresponding to peak periods of differentiation when metabolic demands are especially high. The period of fastest dendritic outgrowth in rat brain is between 8 and 14 postnatal days, whereas in the human is during the first 2-3 years (Uylings, 2000) .
L-Tyrosine can interfere in the development of the cholinergic system through the dopaminergic system. Cholinergic cells in the pons project to DA-rich cell body regions in the ventral tegmental area and substantial nigra where they modulate the activity of dopaminergic neurons and reward processing. The dopamine terminal region of the nucleus accumbens contains a small but particularly important group of cholinergic interneurons, which have extensive dendritic arbors that make synapses with a vast majority of nucleus accumbens neurons and afferents. Together with acetylcholine input onto dopamine cell bodies, cholinergic systems could serve a vital role in gating information flow concerning the motivational value of stimuli through the mesolimbic system (Mark et al., 2011) . Thus, we believe that an increase in the tyrosine levels, consequently increase the syntheses of catecholamines and interfere in the development of the cholinergic system.
In the present study, the expression of ache were significantly decreased after chronic administration of L-tyrosine in striatum and the AChE activity was increased, suggesting that this region Fig. 1 . Effect of acute administration of L-tyrosine on acetylcholinesterase activity (lmol of ACSch per hour per mg protein) in hippocampus, striatum, cerebral cortex and serum of 10-day-old rats (A), 30-day-old rats (B), and effect of chronic administration of L-tyrosine on AChE activity in hippocampus, striatum, cerebral cortex and serum of rats (C). Data are expressed as mean ± standard deviation (mean ± SD of 5-6 animals per group). Different from control, ⁄ p < 0.05 (Student's t test).
is not directly related to a higher ache expression. The transcription machinery is continuously controlled by transcription/translation regulation, protein-protein interactions/modifications and a metabolic network, together forming a system that allows the cell to respond sensibly to the multiple signal molecules that exist in its environment (Krishna et al., 2006) . The phenomenon known as negative feedback loop (Keseler et al., 2005; Salgado et al., 2001) , which is situated at the interface of metabolic and genetic networks, could enlighten the concomitant increase of ACh hydrolysis and the decrease of ache levels in hippocampus after acute administration of L-tyrosine. Grifman et al. (1997) ) have also been shown that the catalytic subunit of cAMP-dependent protein kinase (PKA) can phosphorylate AChE at nonconsensus sites. We observed that rat AChE presents a high predicted score of possible phosphorylation sites: S-88 (PKA), T-280 (PKA) and S-593 (PKC) according to analysis performed in NetPhosk, a kinase-specific prediction of protein phosphorylation site tool. In this context, we suggest that PKA phosphorylation performs the activation of AChE activity after chronic administration. Therefore, PKA phosphorylation might be a decisive factor in the change of enzyme conformation, causing an increase in substrate-enzyme affinity and enzyme activity (Aldunate et al., 2004; Das et al., 2001; Melo et al., 2003) .
A possible mechanism for phosphrorylation of PKA is the oxidative stress since that it has involved in different capacitationrelated events, such as, the increase in cAMP levels and activation of the cAMP/PKA-dependent pathway (Aitken et al., 1998; Herrero et al., 2000; Leclerc et al., 1997) . In this context, the study made by Scaini et al. (2012) ) demonstrated that the treatment with antioxidants was able to prevent the increased activity of AChE, but did not change mRNA levels. Thus, we propose that AChE activity is raised in the presence of ROS, since the treatment with antioxidant revert this increase.
Many studies have been undertaken to define the localization of acetylcholinesterase (AChE; EC 3.1.1.7) and its molecular forms in brain (Brimijoin and Hammond, 1996; Koelle, 1963) . Posttranscriptional mechanisms are thought to account for much of AChE's spatial and temporal variation. Different mechanisms may operate in brain. It remains possible that the local AChE content in each brain area reflects the local rate of AChE production, which in turn reflects the local abundance of AChE mRNA (Legay et al., 1993) . A more convincing discrepancy between mRNA and enzyme levels is in the neostriatum, the brain region where AChE is overwhelmingly most abundant. In announcing their cDNA clone for rat AChE, Legay et al. (1993) noted that the striatum was relatively poor in AChE mRNA as measured by Northern blotting. However, it is suggested that the low overall level of striatal ache mRNA reflects a scarcity of neurons, expressing the transcript at high levels, and this may explain the change in the striatum after administration of L-tyrosine. However, the effect of administration of L-tyrosine in the hippocampus is not certainty known. But it is believed that the abundance of the message largely parallels that of the protein itself, the steady-state level of ache mRNA in many brain regions may well reflect the rate of enzyme of biosynthesis.
The physiological consequence that could occur in our results, in the acute and chronic administration, is a compensatory mechanism. This mechanism causes a down-regulation of ache mRNA expression, which in turn reflects in the rate of AChE production, thus the enzyme activity gets normal and the cholinergics transmissions do not cause undesirable effects (Hammond et al., 1994) .
Conclusions
Results demonstrated a marked increase in AChE activity in all evaluated brain areas after administration of L-tyrosine. We suggest that neurological sequelae in tyrosine. Tirosinemic patients is associated with decreased levels of Ach in the synaptic cleft caused by increased activity of AChE, thus contributing to progressive cognitive impairment and other neurological dysfunctions seen in patients affected by tyrosinemia type II.
